SEC filing record
Primary Source · SEC.gov

Nasus Pharma Ltd

2026 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalNew Form D filerForm D · 2026-02-25Last filing 2026-02-25

Raised

$15M

Investors

15

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Nasus Pharma Ltd is a Israel corporation that filed a Form D with the SEC on February 25, 2026 in the Biotechnology industry group. The offering claims Rule 506(b) and covers equity. Nasus Pharma Ltd reported $15,000,040 sold from 15 investors of a $15,000,040 total offering as of the Form D filed February 25, 2026. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names CITIZENS JMP SECURITIES, LLC (CRD 000022208), associated with None; Laidlaw & Company (UK) Ltd. (CRD 000119037), associated with None as recipients of sales compensation soliciting in CA, CO, CT, FL, GA, IL, MA, MD, MI, NJ, NY, OR, PA, TX. Sales commissions are reported as $900,002 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 29 Harakevet St, Tel Aviv - Yafo, Israel 6618003.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0002029039
Entity NameNasus Pharma Ltd
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationIsrael
Issuer Address29 Harakevet St, Tel Aviv - Yafo, Israel 6618003
Phone972 54-255-3956
Industry / Fund TypeBiotechnology
Securities TypeEquity
First Sale DateFebruary 10, 2026
Filing DateFebruary 25, 2026
Accession Number0001493152-26-008057
Total Offering Amount$15,000,040
Total Amount Sold$15,000,040
Amount Remaining$0
Total Investors15
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Sales Commissions$900,002 (to CITIZENS JMP SECURITIES, LLC and 1 other)
Finders' Fees$0
Revenue RangeNo Revenues
State (Issuer Address)L3
Amendment CountOriginal filing only

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

1

latest Feb 25, 2026

Critical / warning

0 / 0

0 watch · 1 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

1

closed

Latest event New filer · Feb 25, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 1 filing event with values and deltas, latest 2026-02-25, and alerts on the next one
  • 1 offering timeline: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Dan Teleman

Executive Officer, Director · TEL AVIV, L3

Chief Executive Officer

Eyal Rubin

Executive Officer · TEL AVIV, L3

Chief Financial Officer and Executive Vice President

Udi Gilboa

Director · TEL AVIV, L3

Dalia Megiddo

Executive Officer, Director · TEL AVIV, L3

Chief Development Officer and Chief Medical Officer

Ronnie Hershman

Director · TEL AVIV, L3

David Silberman

Director · TEL AVIV, L3

Sharon Shacham

Director · TEL AVIV, L3

Isaac Israel

Director · TEL AVIV, L3

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

CITIZENS JMP SECURITIES, LLCCRD 000022208 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in CA, CO, CT, FL, GA, IL, MA, MD, MI, NJ, NY, OR, PA, TX and outside the United States

Laidlaw & Company (UK) Ltd.CRD 000119037 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in CA, CO, CT, FL, GA, IL, MA, MD, MI, NJ, NY, OR, PA, TX and outside the United States

Questions About Nasus Pharma Ltd

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Nasus Pharma Ltd?

Nasus Pharma Ltd is a Israel corporation that filed a Form D with the SEC on February 25, 2026 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.

Is Nasus Pharma Ltd legit?

AltStreet does not rate legitimacy; it reports the public record. Nasus Pharma Ltd filed a Form D with the SEC on February 25, 2026 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $15,000,040 sold to 15 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Nasus Pharma Ltd registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Nasus Pharma Ltd claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Nasus Pharma Ltd raised?

Nasus Pharma Ltd reported $15,000,040 sold from 15 investors of a $15,000,040 total offering as of the Form D filed February 25, 2026.

Who can invest in Nasus Pharma Ltd?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Nasus Pharma Ltd?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Nasus Pharma Ltd and how are they paid?

The Form D names CITIZENS JMP SECURITIES, LLC (CRD 000022208), associated with None; Laidlaw & Company (UK) Ltd. (CRD 000119037), associated with None as recipients of sales compensation soliciting in CA, CO, CT, FL, GA, IL, MA, MD, MI, NJ, NY, OR, PA, TX. Sales commissions are reported as $900,002 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Nasus Pharma Ltd?

The Form D lists 8 related persons: Dan Teleman, executive officer, director (Chief Executive Officer); Eyal Rubin, executive officer (Chief Financial Officer and Executive Vice President); Udi Gilboa, director; Dalia Megiddo, executive officer, director (Chief Development Officer and Chief Medical Officer); Ronnie Hershman, director; David Silberman, director; Sharon Shacham, director; Isaac Israel, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Nasus Pharma Ltd located?

The issuer's address on its SEC filings is 29 Harakevet St, Tel Aviv - Yafo, Israel 6618003. Its phone number of record is 972 54-255-3956. It is organized under the laws of Israel.

How long is the Nasus Pharma Ltd offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.

What is Nasus Pharma Ltd's revenue?

The Form D reports a revenue range of No Revenues.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.